Phase 3
N=277
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)
Sedation
Bottom Line
View on ClinicalTrials.gov: NCT05312385 ↗Enrolled (actual)
277
Serious AEs
16.9%
Results posted
Mar 2026
Primary outcome: Primary: The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients — 70; 77.7 % of time of adequate sedation depth — p=<0.01
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Isoflurane (Drug); Propofol (Drug); Isoflurane (run-ins) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Sedana Medical
- Primary completion
- Apr 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients |
70; 77.7 | <0.01 sig |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Use of Opioids During the Study Treatment Period |
-0.26; -0.05 | 0.0470 sig |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on the Wake up Time at End of Study Drug Treatment |
17; 27 | 0.229 |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Cognitive Recovery After End of Study Drug Treatment |
19; 10; 9; 9; 7; 12 | 0.218 |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Spontaneous Breathing Effort During the Study Drug Treatment Period |
58.9; 58 | 0.724 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Time From Sedation Termination to Extubation in Patients for Whom Study Drug is Terminated for Extubation |
109.5; 160 | 0.066 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Days Alive and Free of Mechanical Ventilation Through Study Day 30 |
21.6; 19.7 | 0.174 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Days Alive and Free of the ICU |
15.4; 13.7 | 0.215 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Delirium and Coma Free Days Until 7 Days After End of Study Treatment |
2.5; 2.4 | 0.785 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 30 Days After Randomization |
38; 22 | 0.219 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization |
53; 28 | 0.501 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 6 Months After Randomization |
58; 31 | 0.415 |
| SECONDARY Other Secondary: Sedaconda ACD-S Device Deficiencies in Patients Receiving Isoflurane |
1 | — |
| SECONDARY Other Secondary: The Use of Restraints in Patients Receiving Isoflurane vs Propofol |
146; 74 | — |
Summary
This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.
Eligibility Criteria
Inclusion Criteria
- Adults ≥18 years of age;
- Patients who are anticipated to require >12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and
- Receipt of continuous sedation due to clinical need for sedation to RASS 72 hours;
- Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT);
- Ventilator tidal volume 1000 mL at Baseline;
- Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening;
- Comfort care only (end of life care);
- Contraindication to propofol or isoflurane;
- Known or family history of MH;
- Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically;
- Allergy to isoflurane or propofol, or have propofol infusion syndrome.
- History of ventricular tachycardia/Long QT Syndrome;
- Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal
- Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc);
- Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study;
- Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization;
- Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for >4 hours;
- Female patients who are pregnant or breast-feeding;
- Imperative need for continuous active humidification through mechanical ventilation circuit;
- Attending physician's refusal to include the patient; or
- Inability to obtain informed consent.
Data sourced from ClinicalTrials.gov (NCT05312385). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.